ClinicalTrials.gg
RecruitingNCT07193927Updated Apr 30, 2026

Investigation of the Efficacy of a Probiotic Mixture in Moderate Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Mechanistic Trial

A Phase 2 interventional study of Lactiplantibacillus plantarum Probiotic Mixture and Placebo comparator containing maltodextrin in MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Fatty Liver Disease, Nonalcoholic and Overweight (BMI > 25), sponsored by AB Biotics, SA. Recruiting at 1 site in Spain. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-30.

Sponsored by AB Biotics, SA (part of Kaneka Corporation) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 78 studies in Non-alcoholic Fatty Liver Disease with a site in Spain — 11 open to participants now, 15 under way, 7 of them phase 3. Non-alcoholic Fatty Liver Disease · Spain.

Planned enrollment
49th of 66
60 · median 206
Started
2026
the only one that year
Phase 2
32 of 78
2 open now
Primary completion
2027-02
later than 3 of 14 live
Registered
76th of 78
by date

Among the 78 studies in Non-alcoholic Fatty Liver Disease with a site in Spain, this one is the 49th largest by planned enrollment of the 66 interventional ones that give a count, is the only one that started in 2026, is one of 32 in phase 2, reaches primary completion later than 3 of the 14 other live ones, and was the 76th registered.

Non-alcoholic Fatty Liver Disease

1,618 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

11 of the 78 studies in Non-alcoholic Fatty Liver Disease with a site in Spain are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 78 studies in Non-alcoholic Fatty Liver Disease with a site in Spain, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate whether a specific probiotic mixture can improve liver health in adults with moderate metabolic dysfunction-associated steatotic liver disease (MASLD).

The main questions it aims to answer are:

Can the probiotics improve liver fat and stiffness as measured by non-invasive imaging (FibroScan® CAP and FAST scores)? Does the probiotic affect other health markers like cholesterol, blood sugar, inflammation, and gut bacteria?

Researchers will compare people taking the probiotic to those taking a placebo (a capsule with no active ingredients) to see if the probiotic has beneficial effects.

Participants will:

Be randomly assigned to take either the probiotic or placebo daily for 6 months.

Attend 3 study visits (at the start, 3 months, and 6 months). Provide blood and stool samples. Undergo liver scans (FibroScan®). Complete a health and nutrition questionnaire.

This study includes adults aged 18-65 with moderate MASLD and certain metabolic health conditions. Participants must not be pregnant, breastfeeding, or taking certain medications or supplements that could interfere with the study.

03

Conditions studied

  • MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
  • Fatty Liver Disease, Nonalcoholic
  • Overweight (BMI > 25)
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged from 18 to 75 years old
  • 25 - 42kg/m2
  • Diagnosed with MASLD and CAP value > 268 dB/m evaluated by FibroScan®
  • High levels (>30 U/L in males and >19 U/L in females)
  • Having at least three of the following features compatible with metabolic syndrome:

    i. Waist circumference ≥ 102 cm in males and ≥ 88 cm in females. ii. Fasting serum glucose (≥ 5.6 mmol/L or 100 mg/dl). iii. (HbA1c ≥ 5.7%/ 39 mmol/L). iv. Diagnosed or treated for type 2 diabetes. v. High blood pressure (≥ 130/85 mmHg). vi. High plasma triglycerides (≥ 1.70 mmol/L or 150 mg/dl). vii. Lower plasma of High-Density Lipoprotein (HDL cholesterol) (≤ 1.0 mmol/L or 40 mg/dl for males and ≤ 1.3 mmol/L or 50 mg/dl for females).

  • Stable weight in the last 3 months (less than ± 4% weight variation).
  • Stable medication or intake of food supplements for a medical condition that can affect study outcomes according to the Investigator's judgement in the last three months prior to study entry (bile salt sequestrants are not permitted).
  • Not planning to change their dietary and lifestyle habits during the study.
  • Willing and able to provide and comply with study procedures.

Exclusion criteria

Exclusion Criteria:

  • Fibrosis scores equal or higher than F2 (≥ 8.0 kPa).
  • History of acute or chronic hepatitis A, B or C, hepatitis, drug-induced liver diseases, severe liver diseases.
  • Prior or pending liver transplantation.

Patients with at least one of the following concurrent conditions:

i. Type I diabetes ii. Uncontrolled type II diabetes ( >8%) iii. Hypertriglyceridemia > 350mg/dl iv. (HIV) infection v. Diagnosis of hemochromatosis

  • Current use of pioglitazone, SGLT-2 inhibitors, or approved drugs for MASLD or steatohepatitis within 8 weeks.
  • Current use of bile salt sequestrants within 8 weeks.
  • Significant gastrointestinal disease, such as inframmatory bowel disease (IBD, short bowel syndrome, chronic or recurrent diarrhoea, coeliac condition.
  • Pancreatic failure, biliary dysfunction (including cholecystectomy and blood abnormalities)
  • Thyroid dysfunction, as assessed by the investigator (clinical criteria)
  • History of:

    i. Cardiovascular disease (ischemic heart disease, heart failure, cerebrovascular disease, periphreal vascular disease).

ii. Cancer or . iii. Gastrointestinal surgery in the previous year (with the exception of appendicitis).

  • Patients with a history of chronic alcohol or drug abuse: > 14 units/week for females and > 21 units/week for male
  • Chronic and heavy smoking (>20 cigarettes a day)
  • Regular intake (> 3 days/week) of other probiotics (including food complements or diary foods with other probiotic strains, e.g. Activia®, Actimel® or similar).
  • Intake of nutraceuticals with an effect on hepatic function such as > 500 mg/day omega-3 fatty acids, high-dose vitamin E supplements or milk thistle (sylibum marianum) extract ot their active ingredients (silymarin, silybin) regularly (> 7 days) in the 15 days before study entry.
  • Current use of systemic , androgens, clopidogrel, digoxin, acenocoumarol, warfarin, phenytoin, topiramate, lithium, tricyclic antidepressants, MAOIs or second-generation antipsychotics, amiodarone, tamixofen and/or diltiazem.
  • History of use (> 3 days) of oral or parenteral antibiotics one month before the study initiation.
  • Chronic use of laxatives.
  • Debilitating illnesses (advanced liver or kidney disease, severe depression, psychotic symptoms, neurological diseases).
  • Current pregnancy (positive urine test) or planning to become pregnant during the study.
  • Breastfeeding at the time of eligibility assessment.
  • Patients who have participated in a clinical trial in the six-month period before the study.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    Probiotic

    Dietary Supplement: Lactiplantibacillus plantarum Probiotic Mixture

  • Placebo comparator
    Placebo

    Dietary Supplement: Placebo comparator containing maltodextrin

Interventions

  • Dietary supplementLactiplantibacillus plantarum Probiotic Mixture

    A daily oral probiotic capsule containing three specific strains of Lactiplantibacillus plantarum (KABP011, KABP012, KABP013) 1,2 billion CFU with vitamin B1, designed to modulate gut microbiota and improve liver health in MASLD patients. It is compared to a placebo in a 6-month, double-blind, mechanistic trial.

  • Dietary supplementPlacebo comparator containing maltodextrin

    Placebo comparator containing maltodextrin

06

What researchers measure

Primary outcomes

  1. Changes in MASLD from baseline

    Evaluated by CAP (controlled attenuation parameter, dB/m) and FAST score \[determined with FibroScan®\]

    Time frame: From enrollment to the end of treatment at 6 months.

Secondary outcomes

  1. Changes from baseline in Liver Fibrosis (kPa)

    Time frame: From enrollment to the end of treatment at 6 months.

  2. Changes form baseline in MASLD related index - FLI

    Evaluated by Fatty Liver Index (FLI)

    Time frame: From enrollment to the end of treatment at 6 months.

  3. Changes form baseline in MASLD related index - FIB-4

    Evaluated by Fibrosis 4 score (FIB-4)

    Time frame: From enrollment to the end of treatment at 6 months.

  4. Changes form baseline in MASLD related index - APRI

    Evaluated by Aspartate aminotransferase-to-platelet ratio index (APRI)

    Time frame: From enrollment to the end of treatment at 6 months.

  5. Changes from baseline in metabolic syndrome score (siMS)

    Time frame: From enrollment to the end of treatment at 6 months.

  6. Changes from baseline in weight (kg)

    Time frame: From enrollment to the end of treatment at 6 months.

  7. Changes from baseline in height (cm)

    Time frame: From enrollment to the end of treatment at 6 months.

  8. Changes from baseline in Body Mass Index (BMI)

    Body Mass Index (BMI) is a person's weight (kg) divided by the square of height (m).

    Time frame: From enrollment to the end of treatment at 6 months.

  9. Changes from baseline in waist circumference (cm)

    Time frame: From enrollment to the end of treatment at 6 months.

  10. Changes from baseline in hip circumference (cm)

    Time frame: From enrollment to the end of treatment at 6 months.

  11. Changes from baseline in waist/hip ratio

    Waist/hip ratio is measured as the waist circumference (cm) divided by the hip circumference (cm).

    Time frame: From enrollment to the end of treatment at 6 months.

  12. Changes from baseline in systolic and diastolic blood pressure.

    Time frame: From entollment to the end of treatment at 6 months.

  13. Changes from baseline in serum analysis of blood-based cell profile.

    Blood count red cell line, white cell line, and platelet line.

    Time frame: From enrollment to the end of treatment at 6 months.

  14. Changes from baseline in serum liver enzyme concentrations

    Aspartate aminotransferase (AST), alanine aminotransferase (ALT), γ-glutamyl transferase (GGT), alkaline phosphatase (AP)

    Time frame: From enrollment to the end of treatment at 6 months.

  15. Changes from baseline in serum analysis insulin resistance-related variables

    Fasting serum glucose, insulin, glycosylated haemoglobin (HbA1c)

    Time frame: From enrollment to the end of treatment at 6 months.

  16. Changes from baseline in serum analysis of cholesterol and fatty acid concentrations:

    Total cholesterol, low-density lipoprotein, high-density lipoprotein, cholesterol, triglycerides.

    Time frame: From enrollment to the end of treatment at 6 months.

  17. Changes from baseline in serum analysis of high-sensitivity C-reactive protein (hsCRP) concentration.

    Time frame: From enrollment to the end of treatment at 6 months.

  18. Changes from baseline in serum analysis of albumin concentration

    Time frame: From enrollment to the end of treatment at 6 months.

  19. Changes from baseline in serum analysis of total bilirubin (TBIL)

    Time frame: From enrollment to the end of treatment at 6 months.

  20. Changes from baseline in serum analysis of kidney function biomarkers

    Uric acid, creatinine (CREA), and blood urea nitrogen (BUN)

    Time frame: From enrollment to the end of treatment at 6 months.

  21. Changes from baseline in serum analysis of thyroid hormones

    Thyrotropin (TSH), thyroxine (T4), triiodothyronine (T3), parathyroid hormone (PTH)

    Time frame: From enrollment to the end of treatment at 6 months.

  22. Changes from baseline in serum analysis of iron binding capacity

    Ferritin, transferrin, binding capacity

    Time frame: From enrollment to the end of treatment at 6 months.

  23. Changes from baseline in serum analysis of electrolytes

    Sodium (Na), potassium (K), chloride (Cl)

    Time frame: From enrollment to the end of treatment at 6 months.

  24. Changes from baseline in serum analysis of estimated glomerular filtration rate

    Estimated glomerular filtration rate (eGFR) measurements developed by the Chronic Kidney Disease Epidemiology (CKD-EPI) collaboration research group.

    Time frame: From enrollment to the end of treatment at 6 months.

  25. Changes from baseline in serum analysis of nutritional and metabolic biomarkers

    Magnesium (Mg), phosphate (P), iron (Fe), calcium (Ca), total protein, cortisol, 25-hydroxyvitamin D.

    Time frame: From enrollment to the end of treatment at 6 months.

  26. Changes from baseline in serum metabolite profile by Elevated Global metabolome analysis (amine/phenol and acid channels CIL LC-MS profiling)

    Quantification of metabolites (around 850 or more), with a minimum confidence of 90% in the identifications.

    Time frame: From enrollment to the end of treatment at 6 months.

  27. Changes from baseline in gut microbiota diversity

    Evaluated through shot gun metagenomics 10GB/spl (Sample QC + Nextera DNA XT (META) Library and NovaSeqX150PE 10 Gb/sample.

    Time frame: From enrollment to the end of treatment at 6 months.

  28. Changes from baseline in gut microbiota relative abundance

    Evaluated through shot gun metagenomics 10GB/spl (Sample QC + Nextera DNA XT (META) Library and NovaSeqX150PE 10 Gb/sample.

    Time frame: From enrollment to the end of treatment at 6 months.

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Feb 2027, 10 months after the start.

Of 132 industry-sponsored phase 2 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 30. This study's planned 10 months is below that.

Counting every sponsor, half of 185 studies reached it within 26 months; a quarter within 16 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 6, 2025
First posted
Sep 26, 2025
StartActual
Mar 20, 2026
Primary completionEst.
Feb 1, 2027
CompletionEst.
Jun 1, 2027
Last update
Apr 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07193927
Lead sponsor
AB Biotics, SA
Responsible party
Sponsor
First posted
Sep 26, 2025
Start date
Mar 20, 2026
Primary completion
Feb 1, 2027 (estimated)
Completion
Jun 1, 2027 (estimated)
Last update
Apr 30, 2026

Study contacts

José Manuel Dr. Fernández-Real, PhD
Contact
jmfreal@idibgi.org
+34 972940200 - 2656

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion